DelveInsight’s “Clear Cell Ovarian Cancer (OCCC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Clear Cell Ovarian Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Clear Cell Ovarian Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Clear Cell Ovarian Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Clear Cell Ovarian Cancer: An Overview
Ovarian cancer is a disease that affects women and originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.
Based on morphological criteria, Epithelial ovarian cancer (EOC) has been divided into subtypes: serous, endometrial, mucinous, and clear cell, representing tissues of the reproductive tract.
Ovarian clear cell carcinoma (OCCC) is the second most common subtype after high-grade serous carcinoma (HGSC). Clear cell carcinoma of the ovary is a rare and distinct histotype of epithelial ovarian carcinomas. Women diagnosed with clear cell carcinomas are usually younger and diagnosed at earlier stages than those with the most common high-grade serous histology.
These tumors typically arise in middle-aged to older adults as a unilateral mass with an average size of approximately 10 cm. The biology and clinical behavior of OCCC are distinct from other EOCs. OCCC has a unique genetic profile characterized by frequent ARID1A and PIK3CA mutations, MET amplification, and rare p53 mutation.
Clear Cell Ovarian Cancer (OCCC) Market Key Facts
-
The rate of new cases of ovarian cancer was 11.2 per 100,000 women per year. The death rate was 6.7 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2014–2019 deaths.
-
In 2018, there were an estimated 235,081 women living with ovarian cancer in the United States. (Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovary Cancer. National Cancer Institute, 2020)
-
The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 15.7% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 92.6%.
-
According to the study by Wong et al. in 2021 named “Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma” ovarian carcinoma is the most lethal gynecologic malignancy in many countries, with an estimated incidence of 290,000 cases and a mortality of 180,000 cases per year worldwide. Ovarian clear cell carcinoma (OCCC) accounts for approximately 5~27% of all ovarian carcinomas.
Clear Cell Ovarian Cancer (OCCC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Clear Cell Ovarian Cancer pipeline therapies. It also thoroughly assesses the Clear Cell Ovarian Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Clear Cell Ovarian Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Clear Cell Ovarian Cancer (OCCC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Clear Cell Ovarian Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Clear Cell Ovarian Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Clear Cell Ovarian Cancer Epidemiology, Segmented as –
-
Total Incident Cases of Ovarian Cancer
-
Mutation-specific Incident Cases of Clear Cell Ovarian Cancer
-
Stage-specific Incident Cases of Clear Cell Ovarian Cancer
-
Diagnosed and Treatable Cases of Clear Cell Ovarian Cancer
Clear Cell Ovarian Cancer (OCCC) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Clear Cell Ovarian Cancer market or expected to be launched during the study period. The analysis covers the Clear Cell Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Clear Cell Ovarian Cancer drugs based on their sale and market share.
The report also covers the Clear Cell Ovarian Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Clear Cell Ovarian Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Clear Cell Ovarian Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
Clear Cell Ovarian Cancer Therapeutics Analysis
The current standard of care in newly diagnosed ovarian clear cell carcinoma is debulking surgery aiming to achieve full cytoreduction. Residual disease following surgery has been shown as a poor prognostic indicator in a number of retrospective studies. Fertility-sparing surgery is an option for stage IA patients on the proviso that adequate staging is conducted.
Adjuvant chemotherapy with carboplatin and paclitaxel is currently recommended for all patients with stage IC2 and above. The role of chemotherapy in stage IA to IC is more uncertain, however, the European Society for Medical Oncology-European Society of Gynecological Oncology (ESMO-ESGO) consensus states that no adjuvant chemotherapy is recommended for patients with stage IA, IB, IC1, and complete surgical staging. However, the effect of adjuvant chemotherapy in early OCCC remains the subject of intense debate on account of the rarity of the disease and the lack of large sample clinical trials.
Clear Cell Ovarian Cancer Companies Actively Working in the Therapeutics Market Include
Genentech, GlaxoSmithKline, Clovis Oncology, AstraZeneca, Clinigen Group, Novartis, Clovis Oncology, Ortho Biotech, Bristol-Myers Squibb, and Many Others.
Emerging and Marketed Clear Cell Ovarian Cancer Therapies Covered in the Report Include:
-
Olvimulogene nanivacirepvec (Olvi-Vec): Genelux Corporation
-
Rucaparib: Clovis
-
Avastin: bevacizumab; Genentech
-
Zejula (niraparib): GlaxoSmithKline
-
Rubraca: Clovis Oncology
-
Lynparza: AstraZeneca
-
Ethyol (amifostine): Clinigen Group
-
Hycamtin (topotecan hydrochloride): Novartis
-
Doxil: Ortho Biotech
-
Paraplatin: Bristol-Myers Squibb
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Clear Cell Ovarian Cancer Competitive Intelligence Analysis
4. Clear Cell Ovarian Cancer Market Overview at a Glance
5. Clear Cell Ovarian Cancer Disease Background and Overview
6. Clear Cell Ovarian Cancer Patient Journey
7. Clear Cell Ovarian Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Clear Cell Ovarian Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Clear Cell Ovarian Cancer Unmet Needs
10. Key Endpoints of Clear Cell Ovarian Cancer Treatment
11. Clear Cell Ovarian Cancer Marketed Therapies
12. Clear Cell Ovarian Cancer Emerging Drugs and Latest Therapeutic Advances
13. Clear Cell Ovarian Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Clear Cell Ovarian Cancer Market Outlook (In US, EU5, and Japan)
16. Clear Cell Ovarian Cancer Companies Active in the Market
17. Clear Cell Ovarian Cancer Access and Reimbursement Overview
18. KOL Views on the Clear Cell Ovarian Cancer Market
19. Clear Cell Ovarian Cancer Market Drivers
20. Clear Cell Ovarian Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/clear-cell-ovarian-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Diabetic Eye Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetic Eye Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diabetic Eye Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research